Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus

被引:80
|
作者
Groot, N. [1 ,2 ]
Shaikhani, D. [1 ]
Teng, Y. K. O. [3 ]
de Leeuw, K. [4 ]
Bijl, M. [5 ]
Dolhain, R. J. E. M. [6 ]
Zirkzee, E. [7 ]
Fritsch-Stork, R. [8 ,9 ,10 ,11 ]
Bultink, I. E. M. [12 ]
Kamphuis, S. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Rotterdam, Netherlands
[2] Wilhelmina Childrens Hosp, Univ Med Ctr, Utrecht, Netherlands
[3] Leiden Univ, Med Ctr, Leiden, Netherlands
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Martini Hosp, Groningen, Netherlands
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Maasstad Hosp, Rotterdam, Netherlands
[8] Univ Med Ctr, Utrecht, Netherlands
[9] Hanusch Hosp WGKK, Vienna, Austria
[10] AUVA Trauma Ctr, Vienna, Austria
[11] Sigmund Freud Univ, Vienna, Austria
[12] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
关键词
QUALITY-OF-LIFE; DISEASE-ACTIVITY; DAMAGE PROGRESSION; REVISED CRITERIA; RISK-FACTORS; PREVALENCE; MORTALITY; CLASSIFICATION; RHEUMATOLOGY; VALIDATION;
D O I
10.1002/art.40697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life (HRQoL) of adults with childhood-onset SLE. Methods Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI-2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed. Results In total, 111 childhood-onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI-2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease-modifying antirheumatic drugs. The vast majority of new childhood-onset SLE-related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI-2K score >= 8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively). Conclusion The majority of adults with childhood-onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug-free remission, illustrating the substantial impact of childhood-onset SLE on future life.
引用
收藏
页码:290 / 301
页数:12
相关论文
共 50 条
  • [41] A LONG-TERM IMMUNOLOGICAL STUDY OF CHILDHOOD ONSET SYSTEMIC LUPUS-ERYTHEMATOSUS
    TING, CK
    HSIEH, KH
    ANNALS OF THE RHEUMATIC DISEASES, 1992, 51 (01) : 45 - 51
  • [42] Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus
    Semo-Oz, Rotem
    Wagner-Weiner, Linda
    Edens, Cuoghi
    Zic, Carolyn
    One, Karen
    Saad, Nadine
    Tesher, Melissa
    LUPUS, 2022, 31 (12) : 1508 - 1515
  • [43] Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus
    Colin Thorbinson
    Louise Oni
    Eve Smith
    Angela Midgley
    Michael W. Beresford
    Pediatric Drugs, 2016, 18 : 181 - 195
  • [44] Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus
    Lilleby, V
    Lien, G
    Froslie, KF
    Haugen, M
    Flato, B
    Forre, O
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 503 - 503
  • [45] Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus
    Lilleby, V
    Lien, G
    Froslie, KF
    Haugen, M
    Flato, B
    Forre, O
    ARTHRITIS AND RHEUMATISM, 2005, 52 (07): : 2051 - 2059
  • [46] Pharmacokinetics of Hydroxychloroquine in childhood-onset systemic lupus erythematosus
    Zahr, N.
    Gillion-Boyer, O.
    Bader-Meunier, B.
    Melki, I.
    Urien, U.
    Funck-Brentano, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 42 - 43
  • [47] PREDICTORS OF MORTALITY IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
    Gacem, O.
    Zeroual, Z.
    Arrada, Z.
    Achir, Moussa
    Ladj, M. S.
    RHEUMATOLOGY, 2021, 60
  • [48] Clinicopathology of childhood-onset renal systemic lupus erythematosus
    Olowu, W.
    Adelusola, K.
    Senbanjo, I.
    PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1619 - 1619
  • [49] Rituximab therapy for childhood-onset systemic lupus erythematosus
    Haddad, E
    Willems, M
    Niaudet, P
    Koné-Paut, I
    Bensman, A
    Cochat, P
    Deschênes, G
    Fakhouri, F
    Leblanc, T
    Llanas, B
    Loirat, C
    Pillet, P
    Salomon, R
    Ulinski, T
    Bader-Meunier, B
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 390 - 390
  • [50] An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus
    Vitor Cavalcanti Trindade
    Magda Carneiro-Sampaio
    Eloisa Bonfa
    Clovis Artur Silva
    Pediatric Drugs, 2021, 23 : 331 - 347